Comparative Pharmacology
Head-to-head clinical analysis: HADLIMA versus YUSIMRY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HADLIMA versus YUSIMRY.
HADLIMA vs YUSIMRY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNF-alpha) and neutralizes its biological activity by blocking its interaction with the p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNF, including changes in adhesion molecules and apoptosis.
YUSIMRY (adalimumab-adbm) is a tumor necrosis factor (TNF) blocker. It binds to TNF-alpha and neutralizes its activity, reducing inflammatory responses.
40 mg subcutaneously every 2 weeks; may increase to 40 mg weekly if inadequate response.
Subcutaneous: 200 mg every 2 weeks. For patients with body weight ≥100 kg, consider 200 mg every week. IV: 300 mg as a loading dose on day 1, then 200 mg every 2 weeks subcutaneously.
None Documented
None Documented
Terminal elimination half-life approximately 2 weeks (12-16 days); supports every-2-week dosing in maintenance therapy.
Terminal elimination half-life ranges from 10 to 20 days (mean ~14 days) in adults; consistent with IgG1 monoclonal antibody clearance. Reduced half-life may be observed in patients with high tumor burden or concomitant methotrexate.
Renal: 0.1-0.5% as unchanged drug in urine; biliary/fecal: 70-90% as metabolites; mostly via reticuloendothelial system degradation.
Elimination occurs via reticuloendothelial system with catabolism into amino acids; no significant renal or biliary excretion of intact adalimumab. Mean renal excretion of adalimumab is <1% of dose as intact monoclonal antibody.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor